Incidence of Bacille Calmette-Guérin associated lymphadenitis in healthy children: A systematic review and meta-analysis Authors: BongKyoo Choi, Hyunjeong Cho, Ju-Yeun Lee, Jonghyun Jeong, Sungmun Ryu, Eun-Kyoung Lee, Jaewoo Lee, Sangbaek Koh Published: 2026 ABSTRACT ABSTRACTFew systematic reviews or meta-analyses have addressed on the incidence of Bacille Calmette-Guérin (BCG) lymphadenitis in healthy children. A systematic literature search was independently conducted by two researchers using four English and Korean databases (PubMed, Scopus, KMbase, RISS). The risk of bias was assessed. A total of 52 peer-reviewed journal articles (about 1.8 million children) were included in meta-analyses. The incidence proportion of BCG lymphadenitis ranged from 0.0% to 25.6%. The pooled incidence proportion was 2.5% (95% CI, 1.6–3.6; I2 = 99%). Studies employing active (vs. passive) surveillance reported a significantly higher incidence proportion of lymphadenitis, as did randomized controlled trials (vs. prospective and retrospective cohort studies). Also, the incidence significantly differed according to study quality, publication period, and BCG strain. This study highlights substantial variability in the incidence of BCG lymphadenitis among diverse studies and underscores the influence of surveillance methods, study design, and vaccine strain on reported outcomes.KEYWORDS: BCG, lymphadenitis, systematic review, meta-analysis, children Introduction Tuberculosis (TB) remains a leading cause of infectious disease–related morbidity and mortality worldwide. According to the World Health Organization (WHO) Global Tuberculosis Report 2024, about 10.8 million people developed TB worldwide in 2023. TB remains one of the leading infectious disease killers globally, with approximately 1.1 million deaths among human immunodeficiency virus (HIV)-negative individuals and 161,000 deaths among people living with HIV.1 Despite global efforts toward TB elimination, high-burden countries – predominantly in Asia and Africa – continue to struggle with controlling the spread of Mycobacterium tuberculosis.1 Bacillus Calmette–Guérin (BCG) vaccine, first introduced in 1921, is the only currently licensed vaccine against TB and remains widely used, particularly in countries with high TB incidence.2 It is primarily administered to neonates to prevent severe forms of TB, including TB meningitis and miliary TB.2 While its efficacy against pulmonary TB in adults is variable, BCG vaccination has shown consistent protective effects in infants and young children, contributing to its inclusion in many national immunization programs.3 Although the BCG vaccine has a generally favorable safety profile, adverse events following immunization can occur. Among these, BCG lymphadenitis, which is characterized by regional lymph node enlargement, typically involving the ipsilateral axillary or supraclavicular nodes, is one of the most frequently reported complications.4 The time to onset of suppurative lymphadenitis ranges widely, from 1 week to nearly a year after BCG vaccination.5 Given the widespread use of the BCG vaccine and the potential burden of lymphadenitis as an adverse event, a comprehensive evaluation of its incidence is essential to inform clinical guidelines and vaccination policy. While individual studies have reported widely varying incidence proportions of lymphadenitis following BCG vaccination, few meta-analysis studies have comprehensively synthesized the overall incidence of BCG lymphadenitis through a systematic review.6 In addition, it is uncertain whether the incidence of BCG lymphadenitis significantly differs by vaccine strains. Furthermore, in the literature, identification of BCG lymphadenitis cases is mostly based on passive reports rather than an active surveillance approach.7 Thus, it is likely that the incidence of BCG lymphadenitis will be higher in studies based on an active surveillance approach than in those based on passive reports8; however, it is not yet tested through a meta-analysis. To address these knowledge gaps, the present study was conducted with the following objectives: (1) to determine the incidence distribution of BCG lymphadenitis (including both suppurative and non-suppurative forms) following BCG vaccination in healthy children; (2) to assess whether there is a significant difference in lymphadenitis incidence according to vaccine strain; and (3) to evaluate whether the incidence of BCG lymphadenitis differs significantly depending on the type of surveillance method used (active vs. passive).6 Methods Search strategy and eligibility criteria The study protocol was registered with PROSPERO (Registration No: CRD42024531072).9 This study followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA 2020) guidelines.10 Peer-reviewed, full-text journal articles were eligible for inclusion if they reported the incidence of BCG lymphadenitis in healthy children following primary BCG vaccination. Exclusion criteria included studies involving unhealthy or immunocompromised populations, adult participants, revaccination rather than primary vaccination, insufficient data on lymphadenitis incidence, lack of full-text availability, publication in languages other than English or Korean, and study designs deemed inappropriate for meta-analysis (e.g., case reports). A systematic search of four electronic databases including PubMed, Scopus, KMbase, and RISS was independently conducted by two researchers to identify eligible studies published on or before February 15, 2024. Additional gray literature was identified from two sources: (1) a recent systematic review and meta-analysis on the incidence of BCG lymphadenitis conducted by researchers in India,6 and (2) a previously identified World Health Organization (WHO) report on BCG-related lymphadenitis incidence.8 Relevant studies cited in these sources but not retrieved through the primary database search were also reviewed and included if they met the eligibility criteria. After removing duplicates, titles and abstracts were screened based on the predefined inclusion and exclusion criteria. Full texts of potentially eligible studies were subsequently assessed for inclusion. Four studies were excluded at this stage because, although lymphadenitis incidence was mentioned in the abstract, the full texts were not accessible or were not available in English or Korean.11–14 Data extraction For each study included in the final analysis, data extraction was performed using a standardized data collection form, specifically designed to capture key variables relevant to subgroup analyses. To ensure accuracy and consistency, two researchers independently extracted the data, and a summary of the extracted variables for each included study is provided in Supplementary Table 1. Bias assessment The bias assessment of the studies was conducted with RoB 2.0 for randomized control trial (RCT) studies15 and ROBINS-I for non-RCT studies.16 For the studies included in the meta-analysis, quality assessment was independently performed by two researchers (HC, JJ) from each institution, and the evaluations were subsequently reviewed with the participation of the other two researchers (BC, JL). Any disagreements were addressed through discussion and resolved by consensus. For analyses, the overall judgment about risk of bias for each study was categorized into two groups: high- or low-quality studies. Studies with “low” or “some concerns” about risk of bias by RoB 2.0 and “moderate risk” by ROBINS-I were considered high-quality studies, whereas those with “high” risk of bias by RoB 2.0 and “serious” or “critical” risk of bias by ROBINS-I were considered low-quality studies. Statistical analysis Descriptive statistics were used to summarize the demographic and baseline characteristics of the included studies. Meta-analyses of BCG lymphadenitis incidence were conducted using R program (v4.5.1). The overall incidence of total BCG lymphadenitis was defined as the proportion of children who developed lymphadenitis (both non-suppurative and suppurative) following BCG vaccination. The incidence of suppurative lymphadenitis was defined as the proportion of children who developed suppurative lymphadenitis after BCG vaccination. The pooled effect size, expressed as the incidence proportion, was calculated using an arcsine square root transformation approach to stabilize the variance, as recommended for meta-analyses of proportions with rare events.17,18 Both fixed-effect and random-effects models were applied to estimate the pooled incidence. However, given the presence of between-study heterogeneity, the results from the random-effects models were presented as the main analysis. The pooled incidence was reported along with its 95% confidence interval (CI). Statistical heterogeneity was assessed using the I2 statistic and Cochran’s Q test.19,20 A p-value of less than 0.1 in the Q test was considered indicative of statistically significant heterogeneity, due to the test’s limited statistical power.20,21 In addition, the 95% predictive intervals (PIs) for total and suppurative lymphadenitis were obtained under the random-effects model to reflect the expected range of effect sizes in future similar studies, which is particularly useful in the presence of substantial heterogeneity.18 Subgroup analyses were performed according to predefined criteria specified in the study protocol9: surveillance method of lymphadenitis (active vs. passive), study design (RCT, prospective cohort and retrospective cohort), quality of studies (high vs. low), vaccine strain, and vaccination age (≤1 y vs. >1 y). A sub-analysis by publication period was additionally conducted with consideration of the changes in vaccine formulation and recommended dose over time: during 1955–1976 when both liquid and lyophilized BCG vaccines were used (Period 1); during 1977–2003 when only lyophilized BCG vaccines were used (Period 2); and during 2004–2023 when a dosing volume of 0.05 ml for infants was recommended by the WHO and widely implemented (Period 3). Differences between subgroups were evaluated using the Q statistic, and a p-value of less than .05 was considered statistically significant.18 For a sensitivity analysis, the aforementioned sub-analyses were replicated by publication period. In addition, for the comparison of vaccine strain, more restrictions (active surveillance, high-quality studies, intradermal administration of 0.05 ml, and infants) were exploratorily applied. Publication bias was initially examined visually using funnel plots and then quantitatively assessed using Begg’s rank correlation test.22 Results Search result A total of 1,145 articles were identified through the selected databases. After removing duplicates, titles and abstracts were screened based on the predefined inclusion and exclusion criteria, resulting in 112 articles being selected for full-text review. In addition, seven articles identified through gray literature sources were also included for full-text assessment, bringing the total number of articles at the full-text level to 119. Following full-text review, 52 peer-reviewed journal articles6,8,23–72 met all eligibility criteria and were included in the meta-analysis (Supplement Table 1). The detailed study selection process is illustrated in Figure 1. A flow diagram of selecting peer-reviewed journal articles for the systematic review and meta-analysis. Characteristics and bias assessment of included studies Detailed study characteristics and lymphadenitis incidence data for each included articles are presented in Supplementary Table 2. Among the 52 articles included in the final meta-analysis, 23 came from Asia,6,39–42,44–46,48,51–54,56,58,59,61,63,64,66,69,70,72 13 from Europe,23–28,30,31,33,38,57,62,65 10 from Africa,8,29,34,37,47,49,55,67,68,71 5 from the Americas,32,35,36,43,60 and 1 from Oceania.46 Regarding the type of lymphadenitis reported, 47 articles6,8,23–26,28–33,35–37,39–52,54,56–72 included data on total lymphadenitis (both non-suppurative and suppurative), while 34 articles6,23–25,27,29–39,42,45,47–49,53,55–59,61,62,64,65,69,70,72 specifically reported the incidence of suppurative lymphadenitis. During quality assessment, when a single article contained more than one study, each study was evaluated separately. As a result, although 52 articles were included, the total number of studies for quality assessments was 55, because three articles each contributed to two studies.8,33,58 Of the 55 studies, 15 RCTs were evaluated using the RoB 2.0 tool. Among these, five were rated as having “low risk,”55,65,67,68,71 nine as having “some concerns,”23–26,31,33,36,39,47 and one as having “high risk”60 of bias. The remaining 40 studies were non-RCT studies (prospective or retrospective cohort studies), evaluated using the ROBINS-I tool. Among these, 22 were rated as having “moderate”8,27,28,30,34,37,40,43–46,49–51,53,54,56–58,66,69,72 and 18 as having “serious”6,8,29,32,33,35,38,41,42,48,52,58,59,61–64,70 risk of bias. None of the non-RCT studies were rated as having “low” risk, largely because, unlike RCTs, they typically lacked pre-registered study protocols which limited the ability to confirm prespecified methods and outcomes. Studies with a high risk of bias were frequently flagged in Domain 5 (bias in selection of the reported result) of RoB 2.0 for RCTs and Domain 5 (bias due to missing data) of ROBINS-I for non-RCTs. A summary of the risk of bias assessments for all 55 study evaluations is provided in Supplementary Figure 1 and Figure 2. Outcomes of meta-analyses for the incidence proportions of total and suppurative lymphadenitis A total of 79 estimates of total BCG lymphadenitis derived from 52 articles were included in the meta-analysis (Supplementary Table 1). The pooled incidence proportion of lymphadenitis was 2.5%, based on 3,372 cases among 1,790,690 vaccinated individuals (95% CI: 1.6–3.6%, I2 = 99.0%) (Table 1). Forty-two out of 79 estimates (53.2%) were greater than 1%, and the incidence proportions varied widely, ranging from 0.0% to 25.6%. The 95% PI for total lymphadenitis in a future study was from 0.0% to 18.6%. The incidence of suppurative lymphadenitis was reported in 34 articles. The pooled incidence proportion was 0.4% (95% CI: 0.2–0.9%, I2 = 98.3%) with considerable variation between studies. The 95% PI for total lymphadenitis in a future study ranged from 0.0% to 7.2%. Table 1.Results of meta-analyses for total and suppurative lymphadenitis.TypeNumber of Articles (Number of estimates)Events/Total populationPooled effect size (95% CI)Range (PI)I2Total lymphadenitis52 (79)3,372/1,790,6902.5 (1.6–3.6)0.0–25.6 (0.0–18.6)99.0%Suppurative lymphadenitis34 (60)1,088/1,682,5440.4 (0.2–0.9)0.0–26.6 (0.0–7.2)98.3%CI, Confidence Interval; PI, Prediction Interval. Results of meta-analyses for total and suppurative lymphadenitis. CI, Confidence Interval; PI, Prediction Interval. Results of sub-analyses for total and suppurative lymphadenitis Subgroup analyses for total and suppurative lymphadenitis were conducted. The results for total lymphadenitis were presented in Table 2. The pooled incidence of total lymphadenitis varied significantly across study characteristics and I2 values exceeded 90% in all subgroup analyses. When stratified by surveillance method, studies employing active surveillance6,8,23–26,28–31,33,36,37,39,40,42,43,45–51,56–58,63,65–69,71,72 reported a markedly higher pooled incidence of total lymphadenitis (3.7% [95% CI: 2.3–5.5]) compared to those using passive surveillance8,32,33,35,38,41,44,52,54,58–62,64,70 (0.6% [95% CI: 0.2–1.2]). This difference was statistically significant (p < .001, Table 2). Table 2.Results of subgroup analysis in the meta-analyses for total lymphadenitis based on 79 estimates from 52 articles.Sub-analysisNumber ofEstimateEvents/Total populationRandom effect models: Pooled effect size (95% CI)Range(PI)Surveillance method Active551215/114,1113.7(2.3–5.5)0.0–25.6(0.0–23.4) Passive242157/1,676,5790.6(0.2–1.2)0.0–14.8(0.0–5.7)Study design RCT33479/20,2085.5(3.2–8.4)0.0–25.6(0.0–29.1) Prospective non-RCT26964/130,4451.4(0.6–2.5)0.0–18.1(0.0–10.8) Retrospective non-RCT201929/1,640,0370.7(0.2–1.6)0.0–14.8(0.0–8.3)Quality of studies High52929/51,1864.2(2.7–6.1)0.0–25.6(0.0–24.1) Low272443/1,739,5040.5(0.2–0.9)0.0–14.8(0.0–4.6)BCG Strain Danish341403/888,0043.6(1.8–6.1)0.0–25.6(0.0–26.0) Pasteur12955/54,5444.1(2.1–6.7)0.9–18.1(0.0–17.4) Tokyo IDa674/289,8530.1(0.0–0.7)0.0–2.3(0.0–3.5)Vaccination age ≤1 y602,565/1,718,9041.9(1.1–3.0)0.0–25.6(0.0–15.8) >1 y8372/35,6820.7(0.0–2.5)0.0–7.4(0.0–11.6)Publication period 1955–197624355/7,1565.7(3.1–9.1)0.0–25.6(0.0–29.5) 1977–2003302,076/209,7202.5(1.2–4.4)0.0–18.1(0.0–19.1) 2004–202325941/1,573,8140.4(0.2–0.8)0.0–25.0(0.0–3.6)aFor this comparison, BCG Tokyo strain vaccines administered intradermally.CI, Confidence Interval; PI, Prediction Interval; RCT, Randomized Controlled Trial; ID, Intradermal. All subgroup analyses, except for vaccination age, were statistically significant (p < .001). Results of subgroup analysis in the meta-analyses for total lymphadenitis based on 79 estimates from 52 articles. aFor this comparison, BCG Tokyo strain vaccines administered intradermally. CI, Confidence Interval; PI, Prediction Interval; RCT, Randomized Controlled Trial; ID, Intradermal. All subgroup analyses, except for vaccination age, were statistically significant (p < .001). Subgroup analysis by study design revealed that RCTs demonstrated a significantly higher incidence proportion of total lymphadenitis: RCT 5.5% (95% CI: 3.2–8.4) vs. prospective study 1.4% (95% CI: 0.6–2.5) vs. retrospective study 0.7% (95% CI: 0.2–1.6) (p < .001, Table 2 and Figure 2). Forest plots of lymphadenitis incidence by study design: (a) Randomized Control Trials (RCTs), (b) prospective non-RCT studies and (c) retrospective non-RCT studies. RCT, Randomized Controlled Trial; PRO, Prospective Non-RCT; RETRO, Retrospective Non-RCT; D, Danish strain; P, Pasteur strain; T, Tokyo strain; O, Other stains. * Deep dermal administration. ** Lymphadenitis incidence for the Tokyo strain was stratified by injection methods including intradermal and percutaneous administrations. T** refers to the percutaneous administration of the Tokyo strain vaccine. Data on lymphadenitis in WHO23 were based on the enlarged size (>1.5 cm). (Continued). When stratified by study quality, studies classified as high quality8,23–26,28,30,31,33,36,37,39,41,42,45–47,49–51,54,56–58,65–69,71,72 yielded higher incidence proportions (4.2% [95% CI: 2.7–6.1]) compared to those categorized as low quality6,8,29,32,33,35,40,43,44,48,52,58–64,70 (0.5% [95% CI: 0.2–0.9]). This comparison was statistically significant (p < .001, Table 2). A subgroup analysis was conducted on the three most widely used BCG strains globally. The incidence of lymphadenitis was found to be 3.6% for the Danish strain6,23,24,26,33,45,49,51,52,57–59,61,63–65,67,68,70 and 4.1% for the Pasteur strain,29,35–37,41,44,52,54,56,69 both of which were higher than that for the Tokyo strain.41,47,58,70,72 These differences across BCG strains were statistically significant (p < .001, Table 2). The incidence of lymphadenitis was found to be higher in the group vaccinated at ≤1 y of age6,24,25,29,31–33,35–37,39–41,43–46,49–52,54,56–59,61–66,68–72 than in the group vaccinated at >1 y of age8,29,32,47,60; however, the difference was not statistically significant (Table 2). Overall, the results of the subgroup analyses for suppurative lymphadenitis generally mirrored the trends observed for total lymphadenitis (for details, Supplementary Table 2), although statistical significance was identified only in the subgroup analysis of BCG strains. Regarding surveillance methods, studies employing active surveillance6,23–25,27,29–31,33,36,37,39,42,45,47–49,53,55–58,65,69,72 reported a higher pooled incidence of suppurative lymphadenitis (0.5% [95% CI: 0.1–1.1%]) compared to those utilizing passive surveillance32–35,38,59,61,62,64,70 (0.3% [95% CI: 0.1–0.8%]). Similarly, when stratified by study quality, high-quality studies23–25,27,30,31,33,34,36,37,39,45,47,49,53,55–58,65,69,72 yielded a higher incidence rate (0.6% [95% CI: 0.2–1.2%]) than low-quality studies6,29,31,33,35,38,42,48,59,61,62,64,70 (0.2%; [95% CI: 0.0–0.6]). Results of sensitivity analyses The differential patterns in the incidence of total lymphadenitis by surveillance method, study design, vaccine strain, and vaccination age (Table 2) were reexamined within each study period in order to control for the potential period effect. Overall, the results of subgroup analyses in both Period 2 (1977–2003) and Period 3 (2004–2023) were consistent with those presented in Table 2 (for details, see Supplementary Tables 3 and 4), although examining the differential pattern in the subgroup analyses in Period 1 (1955–1976) was limited due to the predominance of studies classified as RCTs, active surveillance methods, and Danish strain (data not shown here). To conduct a more comparable analysis of total lymphadenitis by BCG strain, an additional sensitivity analysis was performed using only studies that met all of the following criteria: active surveillance, high methodological quality, and intradermal administration of 0.05 mL to infants under 1 y of age. The Danish strain was associated with a significantly lower incidence of lymphadenitis, as reflected by a pooled effect size of 0.3% (95% CI: 0.1–0.6, PI: 0.0–1.4) and reduced heterogeneity (I2 = 80.6%). In contrast, the studies of Pasteur strain were found to have a substantially higher incidence, with a pooled effect size of 9.2% (95% CI: 3.4–17.4, PI: 0.0–45.2) (see Figure 3). Forest plots of total lymphadenitis incidence by BCG strain: (a) Danish strain, (b) Pasteur strain and (c) Tokyo strain. Only studies that met the following criteria: active surveillance, high methodological quality, and intradermal administration of 0.05 mL, and infants under one year of age, were included for the above analyses. RCT, Randomized Controlled Trial; PRO, Prospective Non-RCT; RETRO, Retrospective Non-RCT; D, Danish strain; P, Pasteur strain; T, Tokyo strain. Evaluation of risk of publication bias Visual inspection of the funnel plot suggested symmetry, and statistical testing indicated no significant publication bias (Begg’s test p value = .067). Discussion To the best of our knowledge, this is the first systematic review and meta-analysis of examining the incidence of BCG lymphadenitis in healthy children with consideration of potential effect modifiers: surveillance method, study design, quality of studies, BCG strain, vaccination age, and publication period. There was a significant variation of total BCG lymphadenitis in our systematic literature review (95% PI, 0.0–18.6%). The pooled incidence proportion of total BCG lymphadenitis was 2.5% (95% CI: 1.6–3.6%; I2 = 99%). In addition, the pooled incidence of total BCG lymphadenitis significantly differed according to surveillance method, BCG strain, study quality, and publication period. Compared to the only previous meta-analysis of BCG lymphadenitis,6 we would like to emphasize the strengths of our meta-analysis approach: a systematic literature review based on a pre-registered study protocol, using standard bias assessment tools by four researchers for each study, and scrutinizing multiple Korean and English literature databases and gray literature, spanning approximately 70 y (from 1955 to 2023). As a result, we were able to identify and include more than twice the number of articles and over five times the number of children in our meta-analysis. In addition, by including 15 RCT studies in the current study, we were able to compare the incidence of BCG lymphadenitis by three types of study design. On the other hand, we found a substantial variation of total BCG lymphadenitis (about half of 79 estimates were above 1%) in the current study, which is generally consistent with the previous meta-analysis.6 But it was contrasted with some previous studies7,73 in which information on BCG lymphadenitis was heavily relied on post-licensure retrospective cohort studies with passive surveillance (mostly less than 1% of incidence). In this study, regardless of the publication period, the pooled incidence of BCG lymphadenitis was significantly higher in active surveillance studies than in passive surveillance studies. Consistent with our results, a previous study8 in Mozambique reported that the incidence of BCG lymphadenitis was 1.3% in a passive surveillance system, while it was 7.4% with active case-search by a research team. However, to our knowledge, this is the first study to quantify and demonstrate this difference through a meta-analysis. This finding highlights that surveillance intensity can substantially affect reported rates and should be considered when interpreting the results of this meta-analysis. In most countries where infant BCG vaccination is implemented as a National Immunization Program (NIP), pharmacovigilance typically relies on passive surveillance methods. This reliance likely results in an underestimation of the true incidence of lymphadenitis, as minor or transient cases may go unreported. Therefore, to obtain a more precise assessment of BCG lymphadenitis rates for national public health management, more active surveillance approaches need to be recommended. This study also indicates that when it comes to the incidence of BCG lymphadenitis, vaccine strain can be a key factor. In our initial analysis for the three BCG strains, the incidence appeared to be similar between Pasteur and Danish strains (Table 2). However, in our subsequent analysis with more comparable studies (Figure 3), the incidence of lymphadenitis was significantly higher for Pasteur strain than for Danish or Tokyo strains. This finding is consistent with some previous studies in which Pasteur strain vaccines were compared to Danish strain vaccines44 and Glaxo or Tokyo strains.73 While the incidence of total BCG lymphadenitis was 25% in one RCT study of a Danish strain vaccine,67 the total number of vaccinated infants was very small (12 infants). The pooled effect size of lymphadenitis incidence was higher in RCTs compared with non-RCTs (RCT: 5.5% vs. non-RCT prospective: 1.4% vs. non-RCT retrospective: 0.7%). Studies of higher quality (i.e., lower risk of bias) also reported a higher mean effect size (high quality: 4.2% vs. low quality: 0.5%). These findings are another unique contribution of the current study given no comparable studies in the literature. In addition, the findings, consistently observed across all three publication periods, suggest that study design and quality of study should be weighed in the assessment of lymphadenitis risk of BCG vaccines. On the other hand, this is also the first study of investigating and revealing a substantial difference in BCG lymphadenitis between three time periods, reflecting the historical trajectory of BCG vaccines in terms of formulation and dosage. In Period 1 (1955–1976), both liquid and lyophilized BCG vaccines of Danish strains were used in the 1950s and afterward only in lyophilized form. Pasteur strains were introduced as lyophilized BCG vaccines, while there was no BCG vaccine of Tokyo (intradermal) strain. In Period 2 (1977–2003) and Period 3 (2004–2023), Danish, Pasteur, and Tokyo (intradermal) BCG vaccines were all used and in lyophilized form. In addition, in Period 3 (2004–2023), a dosing volume of 0.05 ml for infants was recommended and globally put in practice (for details, Supplementary Table 1). We did not find any evidence for doubting publication bias in our meta-analysis. This may reflect the robustness of our systematic and comprehensive literature review employed in this study. However, this study has a limitation that articles published in languages other than English or Korean were not included in our meta-analysis. During the literature search process, four articles were identified, but excluded from our final meta-analysis, that provided English abstracts but had full texts in other languages (e.g., German, Romanian, and Hungarian).11–14 All the lymphadenitis incidence proportions reported in the excluded four articles fell within the range observed in the current study. A sensitivity analysis with the excluded four articles did not make a difference in our results. Another limitation is the lack of detailed information on each BCG vaccine product in most of the studies included for this meta-analysis, for example, manufacturer of each BCG vaccine product, batch-to-batch variation in potency, or the amount of vaccine per vial (mg). Because these vaccine-related factors could contribute to variability in lymphadenitis incidence,6,74 the inability to account for them may have introduced additional heterogeneity into the pooled estimates of lymphadenitis in the current study. Therefore, this limitation should also be considered when interpreting the findings of this meta-analysis. Despite some key effect modifiers for BCG lymphadenitis identified in this study, a large variation in BCG lymphadenitis even within the same subgroup indicates that more influential modifiers remained to be tested and confirmed in future research. Conclusions We conducted a systematic review and meta-analysis study on BCG lymphadenitis in healthy children. This study, with several methodological strengths, highlights substantial variability in BCG lymphadenitis incidence among 52 articles in the literature. Subgroup analyses showed that the incidence differed significantly according to surveillance methods, study design, study quality, vaccine strain, and publication period. Similarly, the incidence of suppurative lymphadenitis also varied between these subgroups. These findings should be taken into consideration in the risk assessment of BCG lymphadenitis. Supplementary Material Supplemental Material_20251217.docx Acknowledgments We express our sincere thanks to Ms. Sujin Lee (GC Biopharma) and Mr. Jisu Park (Korea University) for their help with the systematic literature review in this study. Biography Bongkyoo Choi serves as the Head of the AI & Data Science Center in the Regulatory Science & Product Development Division at GC Biopharma Corp. He is also an Adjunct Professor in the Department of Biohealth Regulatory Science at Sungkyunkwan University, Republic of Korea. His research interests include pharmacoepidemiological studies, investigating the safety and effectiveness of vaccines and Immunotherapeutics using real-world data to support regulatory decision-making. Disclosure statement No potential conflict of interest was reported by the author(s). Supplemental material Supplemental data for this article can be accessed online at https://doi.org/10.1080/21645515.2026.2662756 References Associated Data Supplementary Materials Supplemental Material_20251217.docx